New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 8, 2013
09:11 EDTWCRX, RVBD, WAG, AOL, LNKD, SKUL, NUAN, RSH, MCD, CXW, CSTR, ONCY, AXL, ATVIOn The Fly: Pre-market Movers
UP AFTER EARNINGS/GUIDANCE: LinkedIn (LNKD), up 11.8%... Activision Blizzard(ATVI), up 8.6%... AOL (AOL), up 6.3%... American Axle (AXL), up 1.3%... ALSO HIGHER: RadioShack (RSH), up 6.8% after appointing former Walgreen (WAG) executive Joseph Magnacca as CEO... Oncolytics Biotech (ONCY), up 34.5% after announcing Phase 2 clinical trial data... DOWN AFTER EARNINGS/GUIDANCE: Nuance (NUAN), down 16.8%... Riverbed (RVBD), down 13.2%... Coinstar (CSTR), down 8.8%... Skullcandy (SKUL), down 8.3%... Warner Chilcott (WCRX), down 4.8%... ALSO LOWER: Corrections Corp. (CXW), down 3.3% after authorizing REIT conversion, declaring $650M-$700M special dividend... McDonald's (MCD), down 0.4% after reporting January global SSS down 1.9%.
News For LNKD;ATVI;MCD;AOL;AXL;RSH;WAG;ONCY;NUAN;RVBD;CSTR;SKUL;WCRX;CXW From The Last 14 Days
Check below for free stories on LNKD;ATVI;MCD;AOL;AXL;RSH;WAG;ONCY;NUAN;RVBD;CSTR;SKUL;WCRX;CXW the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
April 11, 2014
07:59 EDTATVIActivision Blizzard could be pressured by lock-up expiration, says Argus
Subscribe for More Information
06:47 EDTLNKDSamsung ups S5 incentives to fend off rivals, Bloomberg says
Subscribe for More Information
06:08 EDTRVBDRiverbed initiated with a Neutral at SunTrust
Subscribe for More Information
April 10, 2014
11:28 EDTWAGWalgreens management to meet with BB&T
Subscribe for More Information
11:23 EDTWAGRite Aid hits 52-week high after results, sales view top estimates
Shares of retail drugstore Rite Aid (RAD) are rallying after the company's fourth quarter results and fiscal 2015 revenue outlook topped analysts' consensus estimates. WHAT'S NEW: This morning, Rite Aid reported fourth quarter adjusted earnings per share of 10c and revenue of $6.6B, compared to expectations of 4c and $6.54B, respectively. Q4 same store sales increased 2.1%. Rite Aid forecast FY15 EPS of 31c-42c, compared to the consensus of 35c. FY15 revenue was seen at $26B-$26.5B, ahead of the consensus $25.75B. FY15 same-store sales are expected by the company to be up 2.5%-4.5%. WHAT'S NOTABLE: Rite Aid also announced it has acquired RediClinic, which currently operates 30 clinics in the greater Houston, Austin and San Antonio areas. Rite Aid CEO John Standley said, “Our recent acquisitions of Health Dialog and RediClinic, our expanded partnership with McKesson and our continued commitment to investing in our store base have positioned us to transition our strategy from turnaround to growth as we more aggressively pursue opportunities to become a growing retail healthcare company.” PRICE ACTION: In late morning trading, Rite Aid rose 71c, or about 11%, to $7.11 on more than twice its average daily trading volume. Earlier in the session, the stock hit a fresh 52-week high of $7.39. Including today's advance, the stock is up approximately 300% over the past twelve months. OTHERS TO WATCH: Other retail drugstore operators include Walgreen Company (WAG) and CVS Caremark (CVS).
10:44 EDTLNKDStocks with call strike movement; FSLR LNKD
Subscribe for More Information
09:06 EDTCXWCCA announces David Garfinkle to succeed Todd Mullenger as CFO
CCA announced that David Garfinkle, who currently serves as the company's vice president of finance and controller, has been selected by the board to succeed Todd Mullenger as the company's CFO effective May 1. Mullenger has decided to step down as CFO, but will remain with the company for a two-year period to assist in the transition and to assist in various projects.
April 9, 2014
10:06 EDTLNKDOn The Fly: Analyst Upgrade Summary
AmSurg (AMSG) upgraded to Buy from Hold at Cantor... CBOE Holdings (CBOE) upgraded to Buy from Neutral at BofA/Merrill... Carlyle Group (CG) upgraded to Outperform from Perform at Oppenheimer... FireEye (FEYE) upgraded to Buy from Hold at Topeka... Fortune Brands (FBHS) upgraded to Outperform from Neutral at Credit Suisse... Gray Television (GTN) upgraded to Outperform from Market Perform at Wells Fargo... Hibbett Sports (HIBB) upgraded to Overweight from Neutral at Piper Jaffray... LinkedIn (LNKD) upgraded to Buy from Hold at Topeka... Mallinckrodt (MNK) upgraded to Buy from Neutral at UBS... NXP Semiconductors (NXPI) upgraded to Strong Buy from Outperform at Raymond James... Nexstar (NXST) upgraded to Outperform from Market Perform at Wells Fargo... Penn National (PENN) upgraded to Overweight from Equalweight at Barclays... Philip Morris (PM) upgraded to Neutral from Reduce at Nomura... SAIC (SAIC) upgraded to Market Perform from Underperform at Wells Fargo... Sinclair Broadcast (SBGI) upgraded to Outperform from Market Perform at Wells Fargo... Yelp (YELP) upgraded to Buy from Fair Value at CRT Capital... Danaher (DHR) upgraded to Strong Buy from Buy at ISI Group... Quanex (NX) upgraded at BB&T... Omnicell (OMCL) upgraded at Craig-Hallum... Volkswagen (VLKAY) upgraded to Outperform from Market Perform at Bernstein... Magna (MGA) upgraded to Neutral from Sell at Citigroup... Actavis (ACT) upgraded to Positive from Neutral at Susquehanna... E-Trade (ETFC) upgraded to Neutral from Underperform at BofA/Merrill... AmerisourceBergen (ABC) upgraded to Outperform from Market Perform at FBR Capital... CONSOL (CNX) upgraded to Outperform from Neutral at Macquarie.
10:02 EDTAXLBofA/Merrill's US autos/auto parts analyst has analyst/industry conference call
Subscribe for More Information
09:36 EDTLNKDActive equity options trading on open
Subscribe for More Information
09:11 EDTLNKDOn The Fly: Pre-market Movers
Subscribe for More Information
06:33 EDTLNKDLinkedIn upgraded to Buy from Hold at Topeka
Subscribe for More Information
April 8, 2014
16:21 EDTLNKDOn The Fly: Closing Wrap
Subscribe for More Information
09:00 EDTONCYOncolytics Biotech rises 12.4%
Subscribe for More Information
06:38 EDTONCYOncolytics Biotech reports tumor stabilization or shrinkage in REOLYSIN study
Oncolytics Biotech announced additional data from the Company's randomized, double-blinded clinical study examining REOLYSIN in combination with carboplatin and paclitaxel in patients with second-line, platinum-refractory, taxane-naïve head and neck cancers, or REO 018. Highlights include: 118 patients had loco-regional head and neck disease, with or without distal metastases An intent-to-treat analysis of the overall survival, or OS, of the 118 patients with loco-regional disease was performed on all patients to the median PFS in each arm, censoring any patients who received post-discontinuation therapy at the date at which they commenced the first of these therapies. This analysis demonstrated a statistically significant improvement in OS for the test arm versus the control arm; and the 118 patients with loco-regional head and neck disease, with or without distal metastases, were evaluated for percentage magnitude of tumour shrinkage at the first post-treatment scan. The test arm showed a statistical trend towards better tumour stabilization or shrinkage over the control arm. There were 47 patients with distal metastases alone. At the time of the analysis, eight of the 47 patients were still alive. The test arm patients in this group maintained a PFS benefit over control arm patients for five cycles of therapy. There are too few patients to power a statistical analysis of the PFS and OS of this patient group; and the 47 patients with distal metastases alone were evaluated for percentage magnitude of tumour shrinkage at the first post-treatment scan (performed at approximately six weeks). The test arm demonstrated statistically significantly better tumour stabilization or shrinkage than the control arm.
06:37 EDTONCYOncolytics Biotech to host conference call
Conference call to discuss additional data analysis from the Company's REO 018 trial in head and neck cancers will be held on April 8 at 7:45 am. Webcast Link
06:35 EDTONCYOncolytics Biotech announces additional data from REO 018 study of Reolysin
Subscribe for More Information
April 7, 2014
15:16 EDTLNKDLinkedin May volatility elevated as shares trend to 13-month low
Subscribe for More Information
08:53 EDTAOLAOL names William Pence Chief Technology Officer
Subscribe for More Information
07:46 EDTATVITurtle Beach reaches licensing agreement with Blizzard Entertainment
Turtle Beach, the gaming audio brand of Parametric Sound (PAMT), announced a new multi-year licensing agreement with Blizzard Entertainment, a subsidiary of Activision Blizzard (ATVI) around the Heroes of the Storm multiplayer game. As part of the agreement, Turtle Beach will develop PC gaming headsets for players.
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use